Taizhou Overseas Pharmaceuticals

Overseas Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing high-value, differentiated medicines using proprietary drug delivery technologies. The company specializes in the 505(b)(2) regulatory pathway, improving existing drugs to enhance efficacy, safety, and patient compliance. Its core technology platforms, including Solu-Smarter and Sust-Smarter, address challenges in solubility and controlled release. Overseas Pharmaceuticals maintains a robust pipeline targeting central nervous system disorders, oncology, and cardiovascular diseases, with its lead candidate OP-2101 in clinical development for Parkinson's disease. The company operates integrated R&D and manufacturing facilities in both China and the United States.